Adial Pharmaceuticals (ADIL) Research & Development (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Research & Development of $432530.0 for Q1 2026, down 78.38% sequentially from $2.0 million in Q3 2025, and down 42.09% YoY from $746891.0 in Q1 2025.
Adial Pharmaceuticals (ADIL) Research & Development (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Research & Development for 10 years, with the latest figure at $432530.0 in Q1 2026.
- Quarterly Research & Development fell 42.09% year-over-year to $432530.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (down 16.98% YoY) and the FY2025 annual result came in at $2.6 million, down 18.88% from the prior year.
- Research & Development declined to $432530.0 in Q1 2026 per ADIL's latest filing, from $2.0 million in the prior quarter.
- Over five years, Research & Development peaked at $2.5 million in Q3 2024 and troughed at $207128.0 in Q3 2023.
- A 5-year average of $776569.5 and a median of $596341.0 in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2024: Research & Development sank 77.21% in 2022, then surged 1106.23% in 2024.
- Over 5 years, Research & Development stood at $531841.0 in 2022, then sank by 50.28% to $264437.0 in 2023, then soared by 844.81% to $2.5 million in 2024, then dropped by 19.94% to $2.0 million in 2025, then slumped by 78.38% to $432530.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $432530.0, $2.0 million, and $732315.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Adial Pharmaceuticals | 26.99 Mn | 26.99 Mn | - | 440,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 432,530.00 |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 732,315.00 |
| Mar 31, 2025 | 746,891.00 |
| Sep 30, 2024 | 2.50 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 454,278.00 |
| Dec 31, 2023 | 264,437.00 |
| Sep 30, 2023 | 207,128.00 |
| Jun 30, 2023 | 429,896.00 |
| Mar 31, 2023 | 365,616.00 |
| Dec 31, 2022 | 531,841.00 |
| Sep 30, 2022 | 696,073.00 |
| Jun 30, 2022 | 679,966.00 |
| Mar 31, 2022 | 596,341.00 |
| Dec 31, 2021 | 2.33 Mn |
| Sep 30, 2021 | 1.69 Mn |
| Jun 30, 2021 | 77,177.00 |
| Mar 31, 2021 | 2.05 Mn |
| Dec 31, 2020 | -3.54 Mn |